NCT01998217View on ClinicalTrials.gov

Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Pancreatic Stone Disease
Interventions
DRUG

Remifentanil

Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.

DRUG

Flurbiprofen and remifentanil

Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.

Trial Locations (1)

200433

Department of Anesthesiology, Changhai Hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER

NCT01998217 - Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone | Biotech Hunter | Biotech Hunter